Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA4BRV)

Drug Name

Elinogrel Drug Info

Synonyms

Elinogrel; 936500-94-6; UNII-915Y8E749J; 915Y8E749J; 5-CHLORO-N-[[[4-[6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL]PHENYL]AMINO]CARBONYL]-2-THIOPHENESULFONAMIDE; PRT-060128; Elinogrel [USAN:INN]; PRT 060128; Elinogrel (USAN/INN); SCHEMBL160663; CHEMBL2103828; MolPort-035-941-202; ZINC43153259; BDBM50397204; AKOS025142086; NCGC00387478-01; AN-26210; FT-0724857; D09607; 500C946; 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea

Indication

Disease Entry	ICD 11	Status	REF
Myocardial infarction	BA41-BA43	Phase 1	[1]

Cross-matching ID

PubChem CID: 16066663
CAS Number: CAS 936500-94-6
TTD Drug ID: DMA4BRV

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P2Y purinoceptor 12 (P2RY12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[3]
Prasugrel	DM7MT6E	Acute coronary syndrome	BA41	Approved	[4]
Brilinta	DMBR01X	Acute coronary syndrome	BA41	Approved	[5]
Cangrelor	DM8JRH0	Thrombosis	DB61-GB90	Approved	[6]
INS-50589	DMKZUVC	Cardiovascular disease	BA00-BE2Z	Phase 2	[7]
ARL-67085	DMY5IM2	Thrombosis	DB61-GB90	Phase 1	[8]
adenosine diphosphate	DMFUHKP	N. A.	N. A.	Investigative	[3]
2MeSADP	DMGADQ1	Discovery agent	N.A.	Investigative	[9]
2MeSAMP	DMBO2DC	Discovery agent	N.A.	Investigative	[9]
R-138727	DML49FI	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00984113) Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment. U.S. National Institutes of Health.
2	Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
3	P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
4	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5	Clinical pipeline report, company report or official report of AstraZeneca (2009).
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
7	Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
8	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
9	Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
10	Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593-8.